Immunome (NASDAQ:IMNM) Hits New 12-Month High – Here’s What Happened

Shares of Immunome, Inc. (NASDAQ:IMNM) reached a new 52-week high during trading on Wednesday . The company traded as high as $17.94 and last traded at $17.76, with a volume of 262793 shares traded. The stock had previously closed at $17.52.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on IMNM shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a report on Wednesday, October 8th. Craig Hallum initiated coverage on Immunome in a report on Friday, September 5th. They issued a “buy” rating and a $26.00 target price for the company. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Wedbush reissued an “outperform” rating and set a $21.00 price target on shares of Immunome in a research report on Friday, November 7th. Finally, Guggenheim reaffirmed a “buy” rating and set a $25.00 target price on shares of Immunome in a research note on Monday, August 25th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.44.

Immunome Stock Performance

The stock’s 50-day moving average is $13.54 and its two-hundred day moving average is $10.78. The stock has a market cap of $1.57 billion, a PE ratio of -5.81 and a beta of 1.96.

Immunome (NASDAQ:IMNM) last announced its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Analysts forecast that Immunome, Inc. will post -2.21 EPS for the current year.

Institutional Trading of Immunome

Several hedge funds have recently made changes to their positions in the business. Schonfeld Strategic Advisors LLC purchased a new position in shares of Immunome in the third quarter valued at approximately $856,000. Creative Planning lifted its holdings in Immunome by 4.0% during the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after buying an additional 710 shares in the last quarter. Raymond James Financial Inc. boosted its position in Immunome by 168.2% in the 3rd quarter. Raymond James Financial Inc. now owns 10,300 shares of the company’s stock valued at $121,000 after buying an additional 6,459 shares during the period. California State Teachers Retirement System boosted its position in Immunome by 72.2% in the 3rd quarter. California State Teachers Retirement System now owns 65,845 shares of the company’s stock valued at $771,000 after buying an additional 27,605 shares during the period. Finally, Pivotal bioVenture Partners Investment Advisor LLC acquired a new position in shares of Immunome in the third quarter worth $5,884,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.